

---

# Cancer Diagnostics Genomic Instability and Tumor Progression: A Survey

---

[www.surveyx.cn](http://www.surveyx.cn)

## Abstract

This survey paper examines the interconnected processes of cancer diagnostics, genomic instability, and tumor progression, emphasizing their implications for research and treatment. The paper is structured into key sections, beginning with an introduction to foundational concepts and definitions. It explores advancements in cancer diagnostics, including imaging techniques, molecular diagnostics, and AI-driven methods, highlighting their role in enhancing detection accuracy and prognostication. The survey then delves into genomic instability, discussing its mechanisms, technological advancements in detection, and implications for treatment strategies. Tumor progression is analyzed through the lens of biological and molecular mechanisms, the role of the tumor microenvironment, and cellular migration dynamics. The interplay between genomic instability and the tumor microenvironment is also explored, underscoring the complexity of cancer progression. The paper concludes by addressing the challenges and future directions in cancer diagnostics, emphasizing the potential of emerging technologies and AI in advancing cancer research. By integrating insights from these interconnected areas, the survey underscores the importance of a multidisciplinary approach in improving cancer diagnostics, treatment, and patient outcomes.

## 1 Introduction

### 1.1 Structure of the Survey

This survey offers a thorough examination of cancer diagnostics, genomic instability, and tumor progression, emphasizing their interconnections and implications for cancer research and treatment. The paper is organized into key sections, each addressing distinct yet related aspects of the topic.

The survey commences with an *Introduction*, establishing the importance of these processes in cancer research. Following this, the *Background and Definitions* section elucidates core concepts and terminologies in cancer diagnostics and genomic instability, providing a foundational understanding.

The third section, *Cancer Diagnostics*, explores current methods and technologies in cancer detection, including advancements in imaging techniques, molecular diagnostics, biomarkers, and the integration of artificial intelligence to enhance diagnostic accuracy, alongside emerging non-invasive techniques for early detection [1].

In the fourth section, *Genomic Instability*, the survey investigates mechanisms and examples of genomic alterations in cancer development, highlighting advancements in detecting genomic instability and its implications for treatment strategies [2].

The fifth section, *Tumor Progression*, analyzes biological and molecular mechanisms driving tumor progression, covering stages of tumor development, the tumor microenvironment's role, and the effects of cellular migration on tumor growth and metastasis [3].

The survey further explores the intricate *Interconnections and Implications* among cancer diagnostics, genomic instability, and tumor progression, detailing how chromosomal instability (CIN) fosters




Figure 1: chapter structure

intra-tumoral heterogeneity, accelerates drug resistance, and influences treatment outcomes. It emphasizes the significance of novel biomarkers, such as genome instability-derived gene signatures, in enhancing prognostic accuracy for aggressive cancers like triple-negative breast cancer (TNBC). Additionally, it discusses how genomic alterations linked to CIN can generate neoantigens affecting immune responses and immunotherapy efficacy. These insights highlight the need for integrating advanced analytical methods and deep learning techniques to refine treatment strategies and improve patient prognoses [4, 5, 6, 7, 8].

The penultimate section, *Challenges and Future Directions*, addresses current challenges in cancer diagnostics and genomic research, discussing emerging technologies and innovations, particularly the role of AI in advancing cancer research, and proposing future research directions and therapeutic strategies [9].

In the *Conclusion*, the study underscores the critical integration of cancer diagnostics, genomic instability, and tumor progression, summarizing key findings that identify specific microRNAs and genome instability-derived genes as both diagnostic and prognostic biomarkers. Notably, five microRNAs were found significant in monitoring lung cancer progression, while an 11-gene signature related to genome instability was established as a reliable prognostic tool for TNBC, enhancing

---

clinical management strategies and understanding of tumor behavior across various disease stages [10, 4]. The following sections are organized as shown in Figure 1.

## 2 Background and Definitions

### 2.1 Core Concepts in Cancer Diagnostics

Cancer diagnostics integrates genomic, molecular, and imaging techniques to accurately identify and characterize malignancies. Genomic instability, particularly aneuploidy, is a hallmark of various cancers and plays a crucial role in tumorigenesis, complicating treatment in heterogeneous cancers like breast cancer [11, 12]. Advances in imaging, such as multiparametric MRI (mpMRI), have improved tumor detection accuracy, addressing overdiagnosis and underdiagnosis, especially in prostate cancer [13]. These are complemented by biosensors, like silicon nanochannel field effect transistor (FET) biosensors, enhancing biomarker detection for early diagnosis [14].

The mechanical properties of cancer cells are increasingly recognized in diagnostics, with alterations in mechanical, thermal, and electrical properties providing insights into tumor biophysics [15]. Yet, these biophysical parameters remain underutilized. A multidisciplinary approach in diagnostics, considering epidemiological factors, clinical presentations, and novel modalities, is vital for strategies tailored to each cancer type [16]. Emerging technologies, such as microbial-based diagnostics, use microbial signatures for early cancer detection [17].

The convergence of genomic, molecular, and imaging techniques, alongside biophysical insights, is fundamental for accurate cancer diagnosis. These methods leverage artificial intelligence and deep learning for early detection, precise characterization, and personalized treatment, enhancing targeted therapy development and optimizing patient outcomes [18, 6].

### 2.2 Key Terminologies and Their Relevance

Understanding key terminologies is essential in advancing cancer diagnostics and therapies. 'Nanosensor', 'Nanochannel', and 'Nanowire' denote cutting-edge technologies, particularly in field effect transistor-based biosensors, enhancing biomarker detection sensitivity and specificity in cancers like breast cancer [14]. 'Genome Instability' is pivotal in cancer biology, with genome instability-related long non-coding RNAs (GInLncRNAs) as potential biomarkers, though their clinical significance in lung adenocarcinoma (LUAD) needs further exploration [19]. A comprehensive prognostic signature for triple-negative breast cancer (TNBC) incorporating genome instability-related genes is crucial for personalized treatment [4].

Prostate cancer diagnostics face challenges like limited inter-rater and intra-rater agreement, highlighting the need for objective, technologically advanced tools [20]. 'Microarray' is significant in gene expression analysis, crucial for understanding cancer's genetic landscape. 'Border length' assesses unintended illumination in microarray analyses, affecting gene expression accuracy [21].

'ECM remodeling' and 'tumor microenvironment' are critical in cancer research, relating to immune escape processes and therapeutic strategy development. Understanding ECM and tumor microenvironment influences on cancer progression can lead to novel interventions [22]. Accurate detection and classification of Ki-67 stained cells and evaluation of tumor-infiltrating lymphocyte (TIL) scores in histopathological images are crucial for assessing tumor proliferation and immune response, essential for prognostication and treatment planning [12].

## 3 Cancer Diagnostics

A comprehensive understanding of cancer diagnostics methodologies is essential for advancing detection and treatment strategies. This section explores significant advancements in imaging techniques that serve as pivotal tools for early cancer identification. By examining recent innovations in imaging technologies, insights into enhanced diagnostic accuracy and improved patient outcomes can be gleaned. The following subsection details these advancements, emphasizing their clinical and research implications. Table 1 presents a comprehensive summary of recent advancements in cancer diagnostics, detailing the methods and innovations across multiple categories that significantly contribute to improving diagnostic precision and patient care outcomes. Additionally, Table 3 presents

Category	Feature	Method
<b>Advancements in Imaging Techniques</b>	Data Source Integration Prompt and Morphology Integration Geometric and Structural Enhancement	MMGC-Net[23], MBTC[24] MEP-LDM[25] GP[26]
<b>Molecular Diagnostics and Biomarkers</b>	AI and Computational Integration Genomic and Molecular Profiling Structural and Variability Analysis	HTABS[27], ATGC[28], KCSK[29] GlnLncSig[19], IPSEA[2] FDA[30], TMG[31]
<b>AI-Driven Techniques in Cancer Diagnostics</b>	Feature Extraction and Analysis Interpretability and Focus Training Enhancement Techniques Data Integration Strategies	FCoxPH[32], CNN[33] SGCD[34] STEM[35] GANS[36], MM-TCF[37]
<b>Emerging Non-Invasive Diagnostic Techniques</b>	3D and Depth Analysis Data Fusion and Integration Biomarker Identification	MCF-OCR[38], P-PCI[39] s-CBIR[40] PASA[41]
<b>Significance of Early Detection in Cancer Diagnostics</b>	Diagnostic Enhancement Techniques Feature Extraction Methods Automation and AI Integration Real-Time Assessment	CAMIL[42], SAG[43] WPSD[44] DL-FISH[45] DRM[46]

Table 1: Overview of Recent Technological Advancements in Cancer Diagnostics: This table categorizes and summarizes various innovative methods across five key areas: advancements in imaging techniques, molecular diagnostics and biomarkers, AI-driven techniques, emerging non-invasive diagnostic techniques, and the significance of early detection. Each category highlights specific features and methods that contribute to enhanced diagnostic accuracy and improved patient outcomes.

a comprehensive comparison of recent advancements in cancer diagnostics, detailing the methods and innovations across multiple categories that significantly contribute to improving diagnostic precision and patient care outcomes. As illustrated in ??, the hierarchical structure of advancements in cancer diagnostics encompasses several key categories, including imaging techniques, molecular diagnostics, AI-driven approaches, and emerging non-invasive techniques, all underscoring the significance of early detection. Each category is further divided into subcategories, showcasing specific innovations and methodologies that contribute to enhanced diagnostic accuracy and patient outcomes. This visual representation not only enhances our understanding of the complex landscape of cancer diagnostics but also highlights the interconnections between various technological advancements.

### 3.1 Advancements in Imaging Techniques

Recent advancements in imaging technologies have revolutionized cancer detection by integrating sophisticated computational methods and multimodal approaches. Deep learning techniques, notably convolutional neural networks (CNNs) in various formats, have significantly enhanced image analysis capabilities, improving the accuracy of cancerous tissue identification. Challenges persist in optimizing CNN methodologies to manage computational demands and enhance interpretability [47]. Latent diffusion models, effective in analyzing large datasets like the Patch Camelyon (PCam), improve diagnostic precision by accurately detecting metastatic tissue via binary labeling [25]. Multimodal data fusion, although primarily focused on laryngoscopic images, offers promising potential for improved diagnostic outcomes by integrating text and images [23].

In colonoscopy, traditional methods are limited by restricted fields of view and insufficient depth information, hindering precancerous lesion detection. Geometrically regularized 3D imaging methods propose enhanced visualization capabilities, potentially improving early detection rates [26]. Radiomics has propelled non-invasive cancer diagnostics by enabling quantitative feature extraction from medical images that correlate with tumor phenotypes, refining prognosis predictions and enhancing clinical assessment objectivity [48]. Moreover, AI integration with spectroscopy techniques marks a significant advancement in diagnostic accuracy, with applications in established and emerging spectroscopy methods [49]. In brain tumor classification, multimodal imaging addresses traditional histopathological method limitations, offering improved diagnostic capabilities [24]. To address class imbalances in imaging datasets, methods like SMOTE-ENN for initial oversampling and Mixup for further augmentation have been employed, creating balanced datasets that enhance diagnostic model robustness [35].

As illustrated in Figure 2, significant advancements in cancer diagnostics have emerged, particularly through sophisticated imaging techniques. This figure illustrates the recent advancements in imaging techniques, highlighting key areas such as deep learning enhancements, 3D imaging and radiomics, and dataset balancing methods. These developments significantly contribute to improving cancer

diagnostics accuracy and efficiency. The first example, "Sequential Image Processing: A Visual Explanation," highlights the transformation of images through various processing techniques, emphasizing challenges in maintaining image quality. The second example, "Performance Evaluation of a Medical Image Classification Model," assesses a model's classification accuracy using a confusion matrix, underscoring the importance of model precision in medical diagnostics. Lastly, the "Comparison of Morphology-Enriched and Baseline Image Classification Models for Cancer Detection" reveals that the morphology-enriched model enhances clarity and detail, improving cancerous tissue detection. Collectively, these examples underscore the critical role of advanced imaging techniques in enhancing the accuracy and effectiveness of cancer diagnostics [47, 50, 25].

The continuous advancement of imaging technologies, driven by innovations in AI and multimodal data integration, presents transformative opportunities to enhance cancer diagnostics through improved image analysis accuracy, quantitative assessments via radiomics, and comprehensive tumor classification across diverse imaging modalities [50, 24, 48]. These developments not only enhance detection accuracy and efficiency but also pave the way for personalized and targeted therapeutic interventions.




Figure 2: This figure illustrates the recent advancements in imaging techniques, highlighting key areas such as deep learning enhancements, 3D imaging and radiomics, and dataset balancing methods. These developments significantly contribute to improving cancer diagnostics accuracy and efficiency.

### 3.2 Molecular Diagnostics and Biomarkers

Molecular diagnostics and biomarkers are essential for precise cancer identification and characterization, providing insights into the genetic and molecular mechanisms of tumorigenesis. Recent advancements have significantly improved cancer detection accuracy through the integration of computational methods with molecular diagnostics. High-throughput pan-cancer screening methods utilizing artificial intelligence on routine HE whole slide images have been proposed for rapid and cost-effective screening of multiple molecular biomarkers, addressing the challenges of traditional assays [27]. The importance of histopathological characteristics in cancer diagnostics is emphasized by the need for effective representation of whole slide images (WSIs). The SlideGCD framework exemplifies efforts to enhance cancer identification through improved WSI representation, crucial for capturing intricate tissue morphology details [34]. The detection and classification of bi- and multi-nucleated tumor cells in histological images, as highlighted by the BI benchmark, further illustrate advancements in histological analysis [51].

Incorporating imaging data with computational models, such as integrating reaction-diffusion PDE models with multiparametric MRI data, enhances tumor growth prediction robustness by automatically extracting tumor growth parameters and initiation locations (TIL) [28]. These approaches exemplify the synergy of imaging and computational techniques in refining molecular diagnostics. Exploring genomic instability-related long non-coding RNAs (GInLncRNAs) as biomarkers has advanced the understanding of cancer biology, particularly in lung adenocarcinoma (LUAD). Prognostic models based on GInLncRNA expression levels highlight their potential as indicators of genomic instability and their clinical prognostic value [19]. Additionally, integrating protein sequence embeddings with expression levels has improved breast cancer subtype classification, underscoring the importance of comprehensive molecular profiling [2].

Innovative approaches, such as analyzing fractal dimensions in stained pancreatic tissues, provide novel insights into cancer stages, emphasizing structural analysis in molecular diagnostics [30]. The Tumor Mass within Gross Tumor Volume (TMG) method incorporates tumor heterogeneity into survival analysis, offering a nuanced understanding of tumor dynamics compared to traditional methods [31]. Quantum machine learning techniques have also been explored to enhance cancer diagnostics, with experiments using breast cancer diagnostic datasets to assess novel methodologies like the Kerr coherent states kernel, demonstrating improvements over baseline methods [29].

The integration of molecular diagnostics and biomarkers with advanced computational techniques, including artificial intelligence and deep learning, alongside innovative imaging technologies, significantly enhances cancer diagnostic accuracy and efficiency. This transformation is evident in sophisticated models like Convolutional Neural Networks (CNNs), achieving impressive accuracy in distinguishing cancerous tissues, and AI-driven platforms streamlining medical image analysis through classification, object detection, and segmentation. Moreover, the application of radiomics for quantitative medical image analysis and nanotechnology for early cancer detection is paving the way for personalized medicine, ultimately leading to improved patient outcomes and more effective treatment strategies [50, 52, 27, 33, 48]. These advancements not only enhance cancer detection precision but also facilitate targeted therapies, thereby improving patient outcomes.

### 3.3 AI-Driven Techniques in Cancer Diagnostics

Method Name	Methodological Integration	Technological Sophistication	Application Versatility
CNN[33]	Deep Learning Frameworks	Convolutional Neural Network	Imaging Analysis
SAG[43]	Semantic Guidance Integration	Sag Framework Innovation	Cancer Diagnostics Improvement
GANS[36]	Deep Learning Frameworks	Geometry-aware Neural	Imaging Analysis
SGCD[34]	Knowledge Distillation	Graph Convolutional Network	Slide-based Graph
MM-TCF[37]	Dual-encoder Cnn	Dual-encoder Cnn	Tumor Classification Framework
DRM[46]	Robotised Palpation	Dimensionality Reduction	Cancer Diagnostics
STEM[35]	-	-	Breast Cancer Classification
FCoxPH[32]	Ai-segmented Images	Persistent Homology Features	Ai-segmented Pathology

Table 2: The table presents a comprehensive overview of various AI-driven methodologies employed in cancer diagnostics, highlighting their methodological integration, technological sophistication, and application versatility. Each method is associated with its respective framework or innovation, showcasing the diversity and complexity of AI applications in enhancing diagnostic accuracy and efficiency.

Artificial intelligence (AI) is pivotal in enhancing cancer diagnostics, transforming traditional methodologies through advanced computational capabilities. The integration of AI, particularly via deep learning (DL) frameworks, has significantly improved tumor detection, characterization, and prognosis by shifting from qualitative to quantitative imaging analysis [53]. CNNs and other DL models have refined mammography image analyses, facilitating accurate identification of cancerous tissues and supporting clinical decision-making [33]. Recent advancements, such as the Semantics-Aware Attention Guidance (SAG) model, exemplify the sophistication of AI-driven diagnostic tools. SAG enhances interpretability and diagnostic accuracy by focusing on clinically relevant regions through heuristic and tissue guidance [43]. Additionally, the Geometry-Aware Neural Solver (GANS) integrates anatomical data to simulate 3D tumor volumes, providing deeper insights into tumor growth dynamics [36]. Table 2 provides a detailed overview of the AI-driven techniques employed in cancer diagnostics, illustrating the integration of advanced computational frameworks and their impact on diagnostic methodologies.

AI's potential extends beyond imaging to novel diagnostic methodologies. For instance, the SlideGCD framework treats WSI classification as a node classification problem within a slide-based graph, leveraging inter-slide correlations to improve diagnostic accuracy [34]. The multi-modal tumor classification framework (MM-TCF) utilizes dynamic PET features alongside MRI data to differentiate tumor progression from treatment-related necrosis, enhancing classification accuracy [37]. Incorporating AI into non-invasive diagnostic techniques, such as robotized palpation, exemplifies its versatility. This approach employs dimensionality reduction methods combined with dynamic modeling to estimate penetration depth and tissue parameters, enhancing diagnostic precision without direct force measurements [46]. AI's role in radiomics is significant, facilitating the extraction of quantitative features from medical images, crucial for accurate cancer diagnosis and prognosis [48].

---

AI's application in addressing class imbalances in imaging datasets is noteworthy, employing methods like SMOTE-ENN and Mixup to generate synthetic samples that better represent minority class distributions, thus improving model training [35]. Additionally, techniques such as persistent homology are utilized to analyze topological features of tumors, offering robust representations that enhance diagnostic capabilities [32]. AI-driven techniques are fundamentally transforming cancer diagnostics by significantly improving detection accuracy, enhancing tumor characterization, and optimizing treatment planning through advanced medical imaging analysis, including classification, object detection, and segmentation. These innovations leverage sophisticated algorithms and models, such as ResNet50 and YOLOv5, to identify abnormalities in medical images while facilitating personalized treatment strategies across various modalities, including radiotherapy, chemotherapy, and immunotherapy. Furthermore, integrating AI with emerging technologies like optical spectroscopy promises to streamline diagnostic processes, making them faster and less invasive, ultimately leading to better patient outcomes [49, 50, 18, 48]. These advancements are set to further refine diagnostic systems, paving the way for personalized and effective cancer care.

### 3.4 Emerging Non-Invasive Diagnostic Techniques

Emerging non-invasive diagnostic techniques are revolutionizing cancer detection by offering novel approaches that enhance diagnostic accuracy and accessibility. Optical tomography has gained prominence as a non-invasive imaging method, providing three-dimensional insights into subcellular structures, crucial for early identification of cancerous changes [38]. Innovative methodologies, such as retrieving depth information from a single phase-contrast image, have been developed, facilitating non-invasive evaluation of three-dimensional tumor morphology and progression [39]. Photoacoustic spectral analysis (PASA) represents another cutting-edge non-invasive technique, specifically targeting collagen detection, a key biomarker in breast cancer diagnostics. By leveraging unique optical and acoustic properties of tissues, PASA identifies molecular changes associated with cancer [41]. Nanotechnology plays a pivotal role in developing non-invasive diagnostic methods, enabling the detection of extracellular cancer biomarkers, cancer cells, and *in vivo* imaging, thus facilitating early and precise cancer detection [52]. The application of nanotechnology exemplifies the shift towards more sensitive and specific detection modalities that minimize patient discomfort and risk.

Advancements in image retrieval systems, such as s-CBIR, enhance diagnostic accuracy by matching sub-images across different modalities. This system transforms images into a common representation space, allowing effective integration of multimodal data, which is instrumental in comprehensive cancer diagnostics [40]. Emerging non-invasive diagnostic techniques utilizing nanotechnology and artificial intelligence not only enhance early cancer detection by identifying specific biomarkers and tissue characteristics but also significantly improve patient management. These methods provide comprehensive insights into tumor biology and progression, enabling personalized treatment strategies and real-time monitoring of therapeutic responses. For instance, advancements in exosomal protein profiling and laser-induced fluorescence spectroscopy facilitate rapid diagnostics without invasive procedures, contributing to more effective patient care and improved outcomes [54, 49, 52, 33, 55]. As these technologies evolve, they promise to transform cancer diagnostics into more efficient, accurate, and patient-friendly processes.

### 3.5 Significance of Early Detection in Cancer Diagnostics

Early detection of cancer is critical for improving patient outcomes, enabling timely intervention when the disease is most treatable. Advanced diagnostic methodologies, such as liquid biopsies, offer non-invasive means for repeated sampling and monitoring of tumor dynamics, crucial for personalized treatment approaches [56]. The integration of artificial intelligence (AI) into diagnostic processes enhances precision, as demonstrated in the SAG framework, which focuses on diagnostically relevant regions, contributing to more reliable cancer diagnostics [43]. In ovarian cancer detection, wavelet packet-based scaling descriptors have significantly improved classification accuracy, achieving test accuracies from 79

In lung cancer, lesion-level models demonstrate superior classification performance, highlighting their clinical utility for precision diagnostics and emphasizing early detection's importance [57]. AI's role in brain tumor management exemplifies its impact, offering improved diagnostic capabilities and personalized treatment strategies [58]. These advancements address the longstanding challenges of

accurate and timely cancer diagnosis, historically limited by the invasiveness, speed, and accuracy of existing techniques [49]. Automation of diagnostic processes, such as HER2 amplification testing, represents a significant advancement in clinical diagnostics, improving speed, objectivity, and interpretability [45]. Moreover, AI-driven approaches enhance diagnostic processes, improve treatment planning, and facilitate personalized medicine in neuro-oncology [53].

Innovative techniques, such as robotized palpation, show potential for real-time estimation of soft tissue characteristics and penetration depth, promising early-stage cancer diagnostics [46]. Collectively, these advancements underscore the critical importance of early detection in cancer diagnostics, improving diagnostic accuracy and significantly influencing treatment strategies and patient survival. Continuous integration of advanced technologies and methodologies enhances the capacity to detect cancer at nascent stages, ultimately leading to better patient outcomes and more effective disease management.

Feature	Advancements in Imaging Techniques	Molecular Diagnostics and Biomarkers	AI-Driven Techniques in Cancer Diagnostics
Data Integration	Multimodal Data Fusion	Genomic And Imaging	Deep Learning Models
Diagnostic Accuracy	Improved Image Analysis	High-throughput Screening	Enhanced Precision
Application Domain	Cancer Imaging	Genetic Profiling	Ai-enhanced Imaging

Table 3: This table provides a comparative analysis of recent advancements in cancer diagnostics across three major domains: imaging techniques, molecular diagnostics and biomarkers, and AI-driven techniques. It highlights key features such as data integration, diagnostic accuracy, and application domains, emphasizing the contributions of each method to improving diagnostic precision and patient care outcomes.

## 4 Genomic Instability

### 4.1 Understanding Genomic Instability

Genomic instability is fundamental to cancer, driving tumorigenesis through microevolutionary processes that enhance tumor progression and adaptation. It is characterized by increased mutation rates, chromosomal rearrangements, and aneuploidy, contributing to cancer cell heterogeneity and adaptability [59]. Chromosomal instability (CIN) results in frequent mitotic errors and structural aberrations, increasing the malignant potential of tumor cells [8].

Subclonal populations within tumors, each with distinct genetic alterations, complicate treatment strategies and impact clinical outcomes by enabling rapid adaptation to selective pressures, including therapies [60]. Multinucleated tumor cells, common in cancers with genomic instability, exemplify the genetic material driving oncogenesis, progression, and resistance [51].

The epithelial-to-mesenchymal transition (EMT) illustrates the dynamic nature of cancer progression, enhancing migratory and invasive capabilities. EMT states (early hybrid, late hybrid, full EMT) are characterized by specific morphological and molecular features that contribute to tumor plasticity and metastasis [61]. In gliomas, ATRX deficiency exacerbates genomic instability, increasing DNA damage and complicating treatment [62]. Differentiating tumor progression from necrosis in glioblastoma underscores the importance of genomic instability in clinical management [37].

Advancements in computational models incorporating covariates in genomic studies highlight the influence of these factors on genomic relationships, emphasizing the need for adaptive approaches accounting for complex tumor microenvironment interactions [63]. Multiparametric imaging data integration enhances parameter estimate accuracy related to tumor growth dynamics, providing insights into mechanisms driving genomic instability [28].

Genomic instability is a critical research area, offering insights into cancer progression mechanisms and informing targeted therapeutic strategies. Ongoing investigations into genomic elements, combined with computational methodologies, hold potential for advancing therapies addressing CIN and aneuploidy, prevalent in various cancers, contributing to evolution, resistance, and prognosis. High-throughput sequencing and integrative analyses of genomic and transcriptomic data can identify unique cancer vulnerabilities, including neoantigen generation, paving the way for innovative interventions enhancing patient responses to therapies, including immune checkpoint blockade and personalized vaccines [5, 7, 64, 8, 65].

## 4.2 Mechanisms Leading to Genomic Instability

Genomic instability, a cancer hallmark, arises from mechanisms undermining genomic integrity, promoting tumorigenesis and progression. A fundamental mechanism is DNA repair process failure, particularly post-methylation repair inadequacies, allowing elevated mutation rates and genetic alterations driving oncogenesis [66].

R-loops, RNA-DNA hybrids, induce replication stress, compromising genomic integrity. DDX41 helicase activity is vital for R-loop unwinding; its dysfunction results in accumulation, exacerbating instability [67]. CIN, with karyotypic abnormalities and aneuploidy, introduces tumor genetic heterogeneity, complicating treatment strategies and leading to resistance [60]. PI3K blockade, upregulating AID expression, exacerbates genomic instability, contributing to lymphoma progression [68].

Innate immune system dysregulation plays a pivotal role in tumor progression and septic responses, creating an inflammatory environment promoting genomic instability [69]. cGAS pathway activation by cytoplasmic DNA adds complexity to cellular responses to instability, though cytoplasmic DNA access mechanisms remain elusive [70].

Microtubule mechanical behavior and associated biochemical signaling pathways contribute to genomic instability, essential for understanding cellular treatment responses and resultant alterations [71]. Tumor invasion model global stability reflects interactions between healthy and tumor cells, influenced by genomic instability [72].




Figure 3: Examples of Mechanisms Leading to Genomic Instability

As depicted in Figure 3, genomic instability underlies mechanisms altering genetic information. The first image illustrates telomerase and shelterin's roles in telomere maintenance, protecting against genomic degradation. The second image highlights tumor cell interaction with KIF18A protein, influencing cell state and potentially driving CIN state transitions. The third image shows ATRX1 knockdown effects, increasing -H2AX foci and chromatin remodeling, illustrating chromatin structure's role in genomic instability [73, 64, 62].

## 4.3 Genomic Alterations and Cancer Progression

Genomic alterations drive cancer progression, serving as evolution markers. Driver mutations accumulate, enhancing tumor growth and contributing to heterogeneity in sizes and development times, conceptualized as a branching model [74]. Telomere dysfunction links compromised integrity to chromosomal aberrations [73]. Micronuclei, from mis-segregated chromosomes, introduce immunostimulatory DNA into the cytoplasm, influencing progression [70].

The tumor microenvironment (TME) influences progression, with microRNAs (miRNAs) modulating immune responses, affecting TAMs, DCs, NK cells, MDSCs, and Tregs, impacting immune evasion and progression [75]. Aneuploidy, with abnormal chromosome numbers, enhances survival and adaptability, facilitating aggressive phenotypes [11]. PI3K inhibition, increasing AID levels, exemplifies signaling pathways amplifying instability through hypermutation and translocations [68].

Defects in DNA repair mechanisms, including mismatch repair, base excision, and homologous recombination deficiencies, drive development and influence responses, underscoring therapeutic tar-

getting importance [5]. Gliomas' accurate mpMRI sub-region segmentation is crucial for progression assessment and survival prediction, highlighting imaging data's role in capturing genomic alterations' dynamic nature [76].

Figure 4 illustrates the hierarchical structure of genomic alterations and their impact on cancer progression, categorizing them into three primary areas: genomic alterations, tumor microenvironment interactions, and DNA repair defects. Each category highlights key elements that drive tumor evolution and complexity. These alterations and TME interactions underscore cancer progression complexity, necessitating comprehensive strategies for tumor evolution.




Figure 4: This figure illustrates the hierarchical structure of genomic alterations and their impact on cancer progression, categorizing them into three primary areas: genomic alterations, tumor microenvironment interactions, and DNA repair defects. Each category highlights key elements that drive tumor evolution and complexity.

#### 4.4 Technological Advancements in Detecting Genomic Instability

Benchmark	Size	Domain	Task Format	Metric
BiNC/MuNC[51]	19,983	Veterinary Pathology	Object Detection	F1 score
MAMA-MIA[77]	1,506	Breast Cancer Imaging	Tumor Segmentation	Dice Similarity Coefficient, Hausdorff Distance
K-means[78]	10,656	Cancer Genomics	Clustering	Within-cluster correlation, Overall fit quality
SHIDC-B-Ki-67[12]	2,357	Histopathology	Cell Detection And Classification	F1 Score, RMSE
LCCB[57]	4,754	Lung Cancer	Classification	AUC-ROC

Table 4: This table presents a comprehensive overview of various benchmarks utilized in genomic instability research, detailing their size, domain, task format, and evaluation metrics. The benchmarks cover diverse areas such as veterinary pathology, breast cancer imaging, cancer genomics, histopathology, and lung cancer, highlighting the multifaceted approaches in current research efforts.

Technological advancements have enhanced genomic instability detection, crucial for understanding progression and resistance. Integrating metabolic PET with structural MRI data exemplifies progress, providing a comprehensive view of metabolism and structure, vital for detecting instability and monitoring progression [37]. The TrAp algorithm deconvolves mixed signals to infer subclone composition and evolutionary relationships, offering insights into heterogeneity and evolution [60]. Table 4 provides an in-depth examination of representative benchmarks that are instrumental in advancing the detection and understanding of genomic instability across different domains.

Datasets focusing on histological features, such as bi- and multi-nucleated tumor cells, advance understanding of instability in specific types, including canine cutaneous mast cell tumors [51]. Integrating computational models, like the Sparse Conditional Distribution Ising Model (SCDIM), facilitates binary network data analysis conditioned on covariates, exploring instability by enabling parameter variations based on covariate values [63].

These advancements are reshaping genomic instability detection, offering precise, efficient, and comprehensive tools for research and clinical applications. Future precision oncology research should prioritize data quality, interpretability, and ethical considerations, investigating AI applications for enhanced diagnosis, treatment personalization, and outcome prediction, addressing healthcare access

---

and outcome disparities. Focusing on multimodal data integration and AI process transparency maximizes AI's transformative potential in improving care and decision-making [18, 58].

#### 4.5 Implications of Genomic Instability in Cancer Treatment

Genomic instability impacts treatment strategies by introducing complexities influencing behavior, resistance, and outcomes. This requires a comprehensive approach integrating genetic, epigenetic, and microenvironmental factors. Degradation of DNA repair mechanisms can lead to increased mutation rates, suggesting enhancing repair pathways could improve efficacy [66].

CIN contributes to heterogeneity, complicating outcomes. Targeting CIN might enhance responses, as ongoing CIN contributes to heterogeneity [8]. Integrating biophysical parameters into practice could enhance prognostic accuracy and inform strategies, offering a nuanced understanding of dynamics [15].

Necroptosis, as a therapeutic target, reveals potential interventions exploiting this pathway to improve outcomes [79]. The tumor microenvironment, particularly PSCs, is crucial for understanding pancreatic development and treatment failures, targeting interactions may offer new avenues [80]. Mathematical models provide frameworks for understanding mutation rates and dynamics, emphasizing the error threshold's importance in treatment [59].

Innovative technologies, like privacy-safe monitoring solutions, enhance real-time strategy adaptation, crucial for personalized medicine [81]. Genomic instability, with chromosomal alterations and mutations, necessitates a comprehensive strategy integrating insights from processes like CIN and aneuploidy, alongside genomic technology advancements. This approach is crucial for developing prognostic biomarkers and strategies, particularly in aggressive cancers like TNBC, where understanding instability dynamics can enhance outcomes and inform decision-making [8, 4]. Leveraging these insights, clinicians can develop effective and personalized interventions addressing genomic instability complexities.

### 5 Tumor Progression

#### 5.1 Tumor Progression Mechanisms

Tumor progression involves a complex interplay of biological and molecular mechanisms transforming neoplastic cells into aggressive malignancies. Central to this is tumor evolution, where genetic aberrations foster unique subclonal populations, highlighting the significance of identifying genetic alterations that drive tumor heterogeneity and adaptability [60]. RNA-binding proteins' dysregulation influences RNA processing and translation, aiding cancer cell adaptation under selective pressures [82]. Metabolic changes, such as lactic acid production, create hostile microenvironments for normal cells, promoting cancer cell survival and proliferation [72]. G-quadruplex (G4) formation, especially in ATRX-deficient contexts, links to replication stress and DNA damage, exacerbating genomic instability and tumor progression [62].

Mathematical models elucidate tumor growth dynamics and treatment responses, especially regarding drug resistance and angiogenesis. Integrating these models with neural parameter estimation techniques, particularly in brain tumors, underscores the necessity of understanding tumor dynamics for optimal treatment planning [83, 24]. Vascular network remodeling transforms normal vasculature into heterogeneous tumor-specific networks, highlighting vascular dynamics' significance in tumor growth and targeted therapies [84]. Collective cell migration and leader-follower dynamics in migrating cell clusters underscore cellular interactions' importance in tumor invasion and metastasis [85].

Training neural networks for tumor progression monitoring using a single patient's longitudinal MRI data poses challenges, particularly without extensive additional training data [81]. Addressing this is crucial for advancing personalized tumor monitoring and treatment strategies.

As shown in Figure 5, tumor progression mechanisms are intricate and multifaceted. The first image contrasts breast cancer cells' dual roles, showing potential to protect against or promote tumor growth depending on the microenvironment. The second image examines cancer's genetic landscape, comparing driver and passenger mutation counts in glioblastoma multiforme (GBM) and pancreatic cancer, revealing a correlation between critical driver mutations and benign passenger mutations. The third image explores the TGF signaling pathway's role in the epithelial-mesenchymal transition




Figure 5: Examples of Tumor Progression Mechanisms

(EMT), a crucial process for cancer metastasis involving gene expression changes that facilitate cancer cell spread [3, 74, 86].

## 5.2 Stages of Tumor Development

Tumor development is a multistage process contributing to malignancy progression and metastasis potential. Understanding lung cancer stages is vital for targeted interventions, enabling specific microRNAs and AI models' identification as diagnostic and prognostic factors, improving patient outcomes [10, 57, 43]. The initiation stage involves genetic mutations conferring a growth advantage to a single cell, followed by the promotion stage, where mutated cells proliferate into a benign tumor mass. During this phase, the tumor remains localized without invasive capabilities, contrasting with mechanisms like collective cell migration, allowing early invasive processes [87, 85].

Progression to malignancy involves further genetic and epigenetic alterations enhancing invasive capabilities and metastasis potential, characterized by increased genomic instability and invasive phenotypes as tumor cells interact with their microenvironment [87]. The transition from localized growth to invasive behavior is facilitated by changes in the tumor microenvironment and specific signaling pathways activation, influencing the tumor's ability to breach tissue barriers and establish secondary sites [88].

Collective cell migration is pivotal during invasion, with cancer cells moving as cohesive groups, enhancing invasive potential. This migration mode is relevant in various cancers, including breast and lung cancer, distinct from solitary cell migration [85]. The dynamics involve transitions between different migration modes and intricate interactions with the environment [88]. The final stage, metastasis, involves cancer cells disseminating from the primary site to distant organs, culminating from genetic and phenotypic adaptations enabling survival in circulation and new tumor colonies' establishment. The multi-type branching process model robustly models these stages, accommodating various fitness landscapes, mutation rates, and cell division times [89].

## 5.3 Role of Tumor Microenvironment

The tumor microenvironment (TME) is crucial in tumor progression, influencing cancer cell behavior and development. Alterations in the extracellular matrix (ECM) regulate cancer progression and metastasis, driven by hypoxia, inflammation, and proteolytic activity from tumor and stromal cells, enhancing invasion and creating an immune-suppressive environment. The ECM supports tumor architecture and facilitates malignancy-driving interactions, necessitating its study for understanding cancer dynamics and developing prognostic biomarkers [22, 90, 3].

Interactions between cancer cells and the ECM involve biochemical and biophysical changes supporting growth and dissemination. Mathematical modeling elucidates these interactions, particularly in collective cell migration, where cancer cells cohesively navigate the ECM, enhancing invasive capabilities [88]. Within the TME, tumor-infiltrating lymphocytes (TILs), including T cells, B cells, and natural killer (NK) cells, modulate immune responses, shaping the tumor's immune landscape and influencing progression and immunotherapy efficacy. TILs' presence and activity can suppress or promote growth, depending on immune activation and suppression balance [91].

---

In pancreatic cancer, interactions between pancreatic cancer cells (PCCs) and pancreatic stellate cells (PSCs) contribute to the desmoplastic reaction, characterized by a dense fibrotic stroma impeding drug delivery and supporting growth. Understanding PCC-PSC dynamics is essential for developing therapeutic strategies targeting the TME's fibrotic components to enhance treatment efficacy [80]. The TME is a complex, evolving entity fundamental to progression, influencing behavior, immune responses, and physical properties. This interplay creates obstacles and opportunities for therapeutic interventions. Heterogeneity and dynamics of these parameters within the TME are crucial for developing effective prognostic markers and personalized strategies overcoming resistance and improving outcomes [87, 22, 18, 15, 86]. Advances in TME understanding, particularly through mathematical modeling and immune cell dynamics studies, hold promise for novel strategies to combat progression and enhance outcomes.

#### 5.4 Role of Cellular Migration in Tumor Progression

Cellular migration is pivotal in tumor progression and metastasis, facilitating the transition from localized tumors to invasive malignancies. Migration occurs through traditional single-cell mechanisms and collective cell migration, where tumor cells move in clusters, maintaining tight junctions, enhancing invasive capabilities and therapy resistance compared to single-cell migration. This mechanism is observed even in early stages, highlighting early detection strategies' importance. The epithelial-to-mesenchymal transition (EMT) contributes to aggressiveness by enabling mesenchymal trait acquisition, promoting invasion and metastasis through various states rather than a simple binary transition [85, 61].

Migration is characterized by cancer cells navigating through the ECM, essential for metastasis, involving a complex interplay of molecular and mechanical factors driving movement, either as groups or individual cells. Recent studies underscore collective migration's significance, where cancer cells coordinate movement through three-dimensional microenvironments, maintaining intercellular connections that enhance invasive potential [92]. The transition from collective movement to uncoordinated single-cell escape marks a critical shift in the metastatic cascade, allowing dissemination and secondary tumor establishment [93].

Mechanobiology of migration is elucidated by models describing cells as self-propelling agents exerting dipolar traction forces, leading to elastic deformations influencing movement [94]. Proteins like Snail, regulated by hypoxic conditions in the TME, modulate dynamics and enhance migratory capabilities [95]. Vimentin, a structural protein, is integral to migration, interacting with microtubules and actin networks, facilitating movement, emphasizing its role in motility [96]. Proteins like SIT suppress metastasis, highlighting intricate pathways regulating migration and progression [97].

Agent-based models study the transition from non-invasive spheroid phenotypes to invasive network phenotypes, demonstrating migration's critical role in progression [98]. Motility-induced mixing transition within growing spheroids, characterized by diverging time scales reminiscent of glassy dynamics, illustrates motility's impact on organization and expansion [99].

#### 5.5 Interplay Between Genomic Instability and Tumor Microenvironment

The interplay between genomic instability and the tumor microenvironment (TME) is crucial in cancer progression, influencing growth, metastasis, and therapeutic resistance. ECM alterations within the TME, driven by hypoxia, inflammation, and proteolytic activity, facilitate invasion and create distinct protein signatures serving as prognostic biomarkers. EMT enables migratory and invasive capabilities, complicating treatment responses and outcomes [90, 61]. Genomic instability, characterized by elevated mutation rates and chromosomal aberrations, fosters diverse tumor cell populations interacting dynamically with the TME, comprising cellular and non-cellular components supporting development and dissemination.

A critical aspect is ECM remodeling, significantly contributing to progression and immune evasion, creating barriers against effective treatments [22]. The ECM facilitates invasion and migration while modulating immune responses, influencing immune surveillance evasion. This remodeling is essential for EMT, driven by genomic instability enhancing invasiveness and metastatic potential [61]. Cellular migration dynamics within the TME are complex, with collective migration playing a significant role in early detection and treatment strategies [85]. Leader-follower dynamics within migrating clusters are influenced by ECM properties, highlighting the microenvironment's role in

---

directing movement [85]. Vimentin expression is crucial for maintaining cell integrity and facilitating migration, underscoring its importance in motility and the interplay between genomic instability and the TME [96].

Furthermore, the microenvironment regulates EMT transitions, influencing behavior and therapy response [61]. Mutualistic interactions among tumor cells, particularly through angiogenesis, drive super-linear growth, emphasizing these interactions' importance within the TME. These interactions are compounded by tumors' physical characteristics, exhibiting behaviors akin to granular solids, reflecting the complex interplay of biochemical and biomechanical processes driving invasion [100].

## 6 Interconnections and Implications

### 6.1 Cancer Diagnostics and Genomic Instability

Understanding the link between cancer diagnostics and genomic instability is pivotal in deciphering tumor behavior, with chromosomal instability (CIN) significantly affecting tumor evolution, heterogeneity, and prognosis across cancers. Targeting genomic instability vulnerabilities could foster novel therapies, including prognostic biomarkers and enhanced immunotherapeutic responses via neoantigens from genomic changes [5, 64, 4]. Elevated mutation rates and chromosomal aberrations complicate cancer progression, necessitating diagnostic techniques that capture these complexities effectively.

Identifying biomarkers indicative of genomic instability is crucial. Multi-omics data and advanced computational tools enhance detection of genomic alterations, enriching cancer biology understanding and informing treatment strategies [60]. Advanced imaging modalities, such as multiparametric MRI and dynamic PET-MRI integration, improve diagnostic accuracy by identifying genomic alterations, reducing unnecessary biopsies [37]. AI-driven solutions, like the TrAp algorithm, enhance precision in identifying subclonal populations from genomic data [60]. However, challenges remain, particularly with human interpretation, which can be time-consuming and error-prone. AI applications in whole slide image analysis offer opportunities for improving diagnostics, despite current methods often overlooking variances among different patient samples [63].

Telomeres significantly influence genomic instability, with telomere shortening acting as a tumor suppressor mechanism. Circumventing this barrier leads to a telomere crisis, increasing genomic instability and cancer progression, highlighting the importance of developing diagnostic techniques that detect early genomic instability signs [22].

Non-invasive diagnostic techniques, such as Raman spectroscopy and robotized palpation, show promise across cancers. Raman spectroscopy, coupled with high-throughput screening, reduces costs and time for biomarker detection, enabling simultaneous screening of multiple biomarkers from a single sample [46]. These advancements underscore the importance of integrating molecular data with diagnostics to enhance cancer progression understanding.

### 6.2 Collective Cell Migration and Metastasis

Collective cell migration is fundamental in cancer metastasis, involving coordinated cell group movement through the ECM, significantly influencing invasion and dissemination. Unlike individual migration, it maintains cell-cell junctions and relies on microenvironmental cues [93]. Diverse models, including discrete, continuum, and hybrid frameworks, offer insights into the underlying mechanisms [88].

Mechanical and metabolic interactions critically influence collective migration, affecting movement directionality, speed, and adaptability to environmental conditions [92]. Key molecules, such as E-cadherin, maintain cell-cell adhesion, while vimentin regulates migration patterns.

Cell adhesion dynamics and chemoattractant secretion modulate collective behavior, impacting invasive potential and metastasis [98]. Understanding how cancer cells navigate tissue barriers and establish secondary tumors is crucial, yet challenges remain in elucidating collective migration complexities, particularly cell-cell junction dynamics and treatment resistance [85].

### 6.3 Implications for Treatment Strategies

The intricate connections among cancer diagnostics, genomic instability, and tumor progression profoundly influence treatment strategies. Understanding these interconnections is vital for devising interventions targeting cancer's multifaceted nature. The ECM's dual role in cancer progression, as both a barrier and facilitator of migration, underscores the importance of targeting ECM remodeling to enhance therapeutic efficacy [3]. AI in medical imaging has improved diagnostic accuracy and reduced analysis time, offering significant advantages in diverse scenarios [50].

Adaptive learning mechanisms in treatment algorithms represent a paradigm shift in cancer therapy, offering tailored approaches by dynamically adjusting parameters based on real-time data, potentially improving outcomes [101]. The relationship between driver and passenger mutations reveals that driver mutations' average selective advantage is small, indicating a need for novel strategies to inhibit progression [74].

Higher EGFR density in tumor clones correlates with aggressiveness and faster expansion, providing a basis for strategies considering tumor dynamics and heterogeneity [102]. Novel approaches to FISH dataset analysis capture complex dependencies, offering insights into progression dynamics and informing precise therapeutic strategies [103].

The EMT-metabolism interplay presents therapeutic targets, as these mechanisms are critical in progression. Understanding these links opens avenues for interventions disrupting metabolic pathways supporting EMT, hindering progression [104]. Targeting molecular signaling pathways influenced by SIT enhances anti-tumor therapies, emphasizing potential molecular interventions [97].

Mathematical modeling is valuable for understanding progression and informing strategies. The TTP framework simulates progression dynamics, offering insights into detection times and fitness landscapes' impact on growth [89]. Models capturing complex interactions in processes, like heterogeneous stem cell dynamics, guide strategies by highlighting potential outcomes.

The tumor microenvironment's role, particularly in vascular network remodeling, emphasizes understanding growth-vascular structure interplay. Targeting the microenvironment could prove effective, as proposed by [84]. Formal modeling of pancreatic cancer cell-stellate cell interactions provides insights into potential therapeutic strategies [80].

## 7 Challenges and Future Directions

The dynamic landscape of cancer research presents complex challenges, particularly in diagnostics, crucial for early detection and characterization of malignancies. Addressing these challenges is essential for developing effective diagnostic methodologies and improving patient outcomes. The following subsection delves into the inherent challenges in cancer diagnostics.

### 7.1 Challenges in Cancer Diagnostics

Cancer diagnostics face significant hurdles that hinder accurate detection and characterization of malignancies. Variability in imaging techniques and tumor biology complexity complicate AI integration into clinical practice, necessitating robust AI model validation to ensure reliability across diverse settings [53]. Traditional diagnostic methods, like MRI analysis, are further challenged by their subjective nature and reliance on invasive confirmation procedures. The lack of comprehensive datasets for specific cellular features, such as bi- and multi-nucleated cells, leads to variability in detection performance among pathologists, complicating standardization [51]. Additionally, limited sample sizes in diagnostic methods compromise model robustness and generalizability [37]. Tumor heterogeneity and the dynamic tumor microenvironment (TME) further complicate reliable biomarker identification for tumor progression and therapeutic response. Sophisticated approaches are needed to accommodate cancer's diverse nature, emphasizing the need for advanced diagnostic methods leveraging technologies like nanotechnology and AI. These innovations aim to enhance the sensitivity, specificity, and efficiency of cancer diagnostics, improving early detection and reducing mortality [1, 52, 33].

---

## 7.2 Emerging Technologies and Innovations

Emerging technologies are poised to address current challenges in cancer diagnostics by enhancing precision, efficiency, and data integration. Techniques like robotized palpation, which combine tactile estimation with ultrasound data, improve diagnostic accuracy by detecting smaller anomalies [46]. The SlideGCD framework, which treats WSI classification as a node classification problem, offers a novel method for improving diagnostic accuracy, with potential applicability to other medical imaging types [34]. Cross-modality sub-image retrieval systems, such as CoMIR, enhance diagnostic accuracy by refining feature selection and matching processes tailored for CoMIR representations [50, 40]. Integrating data-driven approaches with mathematical modeling suggests that machine learning can address challenges in understanding biological processes related to cancer. AI-driven models analyze complex datasets, informing personalized therapeutic strategies and enhancing cancer care [6, 48, 18, 53]. These innovations hold promise for revolutionizing cancer diagnostics by refining and integrating AI approaches with clinical practice, improving early diagnosis and optimizing patient outcomes [18, 33, 6].

## 7.3 AI and Emerging Technologies in Cancer Research

AI and emerging technologies are transforming cancer research by enhancing diagnostic precision, therapeutic interventions, and insights into tumor dynamics. AI automates processes like medical image segmentation, reducing reliance on operator expertise and enhancing accuracy [53]. Radiomics, an AI-driven approach, refines prognosis predictions and supports informed treatment planning by correlating quantitative features from medical images with tumor phenotypes [53]. AI's application in lung cancer diagnostics underscores its potential to refine diagnostic accuracy and improve outcomes [57]. AI models are pivotal in simulating tumor growth dynamics, with future research anticipated to integrate more complex models and machine learning methods [28]. Agent-based models provide a framework for simulating cellular behaviors, offering insights into treatment effects on tumor progression [98]. Understanding collective cell migration, a critical process in metastasis, is another area where AI is contributing significantly [85]. AI's ability to enhance personalized treatment plans is augmented by improved diagnostic accuracy and patient stratification [53]. Future work could expand datasets and improve model generalizability, enhancing AI-driven approaches' robustness in cancer research [12]. Advancements in statistical model checking inform cancer research by providing insights into tumor dynamics and treatment responses [80].

## 7.4 Future Directions in Cancer Research

Future cancer research will explore tumor heterogeneity, treatment resistance, and advanced technology integration to enhance therapeutic strategies. A focus on increased genomic instability associated with PI3K inhibition could lead to novel lymphoma treatments [68]. Exploring EMT dynamics through computational modeling holds therapeutic promise, potentially leading to targeted interventions disrupting metastasis [61]. Advancements in modeling techniques, incorporating stochastic elements and spatial dynamics, are essential for reflecting tumor progression complexities [59]. Integrating multimodal data, including radiomics biomarkers and clinical history, is crucial for guiding personalized treatment strategies [57]. Developing standardized protocols for measuring biophysical properties within tumor microenvironments could lead to novel therapeutic strategies. Further studies are needed to refine models simulating tumor cell interactions, particularly concerning disease progression and the effects of initial conditions [69]. These directions emphasize integrating advanced modeling techniques and multimodal data to advance cancer biology understanding, improving diagnostic and therapeutic strategies.

## 7.5 Emerging Therapeutic Strategies

Recent research highlights promising therapeutic strategies targeting critical pathways and cellular interactions to curb cancer progression and metastasis. Modulating cadherins and ECM confinement, crucial for cell-cell adhesion and migration, may hinder metastatic spread [93]. Stabilizing G-quadruplexes in cancers with genomic profiles similar to those characterized by ATRX deficiency presents a therapeutic avenue by exploiting replication stress and DNA damage [62]. The error threshold for aneuploidy rates provides insights into strategies limiting cancer cell adaptability with high genomic instability [11]. Targeting angiogenesis, informed by the Allee effect, could

---

disrupt vascular networks supporting tumor expansion [105]. Exploring immune dysregulation offers additional intervention pathways, enhancing natural defenses against tumor growth [69]. In vivo studies on SIT and its derivatives are crucial for confirming their therapeutic potential, investigating synergistic effects with existing agents [97]. These strategies emphasize targeting structural components and dynamic interactions within the tumor microenvironment, enhancing cancer therapies' effectiveness through AI and multimodal data integration [58, 53, 18, 6].

### 7.6 Overcoming Technical and Ethical Barriers

Advancing cancer research requires addressing technical and ethical barriers to foster innovation and improve outcomes. Integrating and analyzing large-scale datasets is critical for understanding cancer biology complexity. Developing robust computational models and machine learning algorithms enhances data processing and interpretation, aiding biomarker and therapeutic target identification [65]. Standardizing data collection and analysis protocols across institutions ensures consistent findings, crucial for AI-driven diagnostics [53]. Ethical considerations, particularly patient privacy and data security, are critical. Advanced encryption and secure data sharing frameworks balance innovation with privacy protection [81]. Informed consent in genomic research and personalized medicine requires transparent communication about genetic testing implications, ensuring patient understanding and trust [106, 107, 18, 108, 17]. Addressing ethical implications of emerging technologies, like gene editing and synthetic biology, requires comprehensive guidelines prioritizing safety and societal implications. Aligning these frameworks with societal values facilitates responsible AI and nanotechnology integration in cancer care, improving diagnosis, treatment, and outcomes [18, 52, 33, 58, 17]. By addressing technical and ethical barriers, the cancer research community can encourage innovation and discovery, enhancing cancer diagnosis, treatment personalization, and patient care through AI and nanotechnology [18, 52, 58].

## 8 Conclusion

The convergence of cancer diagnostics, genomic instability, and tumor progression represents a significant leap in both research and clinical domains. The importance of early diagnosis and prompt referral to specialized cancer centers cannot be overstated, as these factors are crucial in enhancing patient survival rates. The implementation of sophisticated imaging techniques, particularly those that advance automated lesion segmentation in PET/CT imaging, demonstrates the transformative potential of these technologies in improving diagnostic precision. The prognostic value of topological features, which reveal significant survival differences between high- and low-risk patient groups, exemplifies the role of innovative computational methodologies in enhancing prognostic assessments. Further exploration into the computational complexity of diagnostic models, especially in relation to BMP e and P-BMP e solutions, underscores the need for ongoing research to refine cancer diagnostic strategies. This survey underscores the importance of a multidisciplinary approach that integrates cutting-edge diagnostics, a nuanced understanding of genomic instability, and insights into the mechanisms of tumor progression. Such an integrated framework not only enriches our understanding of cancer biology but also paves the way for the development of targeted therapies, ultimately improving patient care and outcomes.

---

## References

- [1] Upender Kalwa, Christopher Legner, Taejoon Kong, and Santosh Pandey. Skin cancer diagnostics with an all-inclusive smartphone application, 2022.
- [2] Hossein Sholehrasa. Integrating protein sequence and expression level to analysis molecular characterization of breast cancer subtypes, 2024.
- [3] Margaux Sala, Manon Ros, and Frédéric Saltel. A complex and evolutive character: two face aspects of ecm in tumor progression. *Frontiers in oncology*, 10:1620, 2020.
- [4] Genome instability-derived genes.
- [5] Elaine R Mardis. Neoantigens and genome instability: impact on immunogenomic phenotypes and immunotherapy response. *Genome medicine*, 11(1):71, 2019.
- [6] Khoa A Tran, Olga Kondrashova, Andrew Bradley, Elizabeth D Williams, John V Pearson, and Nicola Waddell. Deep learning in cancer diagnosis, prognosis and treatment selection. *Genome Medicine*, 13:1–17, 2021.
- [7] Soufyan Lakbir, Caterina Buranelli, Gerrit A. Meijer, Jaap Heringa, Remond J. A. Fijneman, and Sanne Abeln. Cibra identifies genomic alterations with a system-wide impact on tumor biology, 2024.
- [8] Laurent Sansregret, Bart Vanhaesebroeck, and Charles Swanton. Determinants and clinical implications of chromosomal instability in cancer. *Nature reviews Clinical oncology*, 15(3):139–150, 2018.
- [9] Abhimanyu Kiran, Chandra Shekhar, Manigandan Sabapathy, Manoranjan Mishra, Lalit Kumar, Navin Kumar, and Vishwajeet Mehandia. Effect of serum starvation on rheology of cell monolayers, 2021.
- [10] Dietrich Kong, Ke Wang, Qiu-Ning Zhang, and Zhi-Tong Bing. Systematic analysis reveals key micrornas as diagnostic and prognostic factors in progressive stages of lung cancer, 2022.
- [11] Domenico Napoletani, Michele Signore, and Daniele C. Struppa. Stem-like adaptive aneuploidy and cancer quasispecies, 2013.
- [12] Farzin Negahbani, Rasool Sabzi, Bita Pakniyat Jahromi, Fateme Movahedi, Mahsa Kohandel Shirazi, Shayan Majidi, Dena Firouzabadi, and Amirreza Dehghanian. Pathonet: Deep learning assisted evaluation of ki-67 and tumor infiltrating lymphocytes (tils) as prognostic factors in breast cancer; a large dataset and baseline, 2021.
- [13] Armando Stabile, Francesco Giganti, Andrew B Rosenkrantz, Samir S Taneja, Geert Villeirs, Inderbir S Gill, Clare Allen, Mark Emberton, Caroline M Moore, and Veeru Kasivisvanathan. Multiparametric mri for prostate cancer diagnosis: current status and future directions. *Nature reviews urology*, 17(1):41–61, 2020.
- [14] Pritiraj Mohanty, Yu Chen, Xihua Wang, Mi K. Hong, Carol L. Rosenberg, David T. Weaver, and Shyamsunder Erramilli. Field effect transistor nanosensor for breast cancer diagnostics, 2014.
- [15] Anja Madleine Markl, Daniel Nieder, Diana Isabel Sandoval-Bojorquez, Anna Taubenberger, Jean-François Berret, Artur Yakimovich, Eduardo Sergio Oliveros-Mata, Larysa Baraban, and Anna Dubrovska. Heterogeneity of tumor biophysical properties and their potential role as prognostic markers, 2024.
- [16] Katharine C DeGeorge, Harry R Holt, and Stephanie C Hodges. Bladder cancer: diagnosis and treatment. *American family physician*, 96(8):507–514, 2017.
- [17] Gregory D Poore, Evguenia Kopylova, Qiyun Zhu, Carolina Carpenter, Serena Fraraccio, Stephen Wandro, Tomasz Kosciolek, Stefan Janssen, Jessica Metcalf, Se Jin Song, et al. Retracted article: Microbiome analyses of blood and tissues suggest cancer diagnostic approach. *Nature*, 579(7800):567–574, 2020.

- 
- [18] Induni N Weerarathna, Aakash R Kamble, and Anurag Luharia. Artificial intelligence applications for biomedical cancer research: a review. *Cureus*, 15(11), 2023.
  - [19] Wei Geng, Zhilei Lv, Jinshuo Fan, Juanjuan Xu, Kaimin Mao, Zhengrong Yin, Wanlu Qing, and Yang Jin. Identification of the prognostic significance of somatic mutation-derived lncrna signatures of genomic instability in lung adenocarcinoma. *Frontiers in cell and developmental biology*, 9:657667, 2021.
  - [20] Ping-Chang Lin, Teodora Szasz, and Hakizumwami B. Runesha. Implementation of convolutional neural network architecture on 3d multiparametric magnetic resonance imaging for prostate cancer diagnosis, 2021.
  - [21] Robert Ganian, Martin Kronegger, Andreas Pfandler, and Alexandru Popa. Parameterized complexity of asynchronous border minimization, 2015.
  - [22] Zhennan Yuan, Yingpu Li, Sifan Zhang, Xueying Wang, He Dou, Xi Yu, Zhiren Zhang, Shanshan Yang, and Min Xiao. Extracellular matrix remodeling in tumor progression and immune escape: from mechanisms to treatments. *Molecular cancer*, 22(1):48, 2023.
  - [23] Zhaojun Jin, Yi Shuai, Yongcheng Li, Lingcong Cai, Yun Li, Huifen Liu, and Xiaomo Fan. Visionllm-based multimodal fusion network for glottic carcinoma early detection, 2024.
  - [24] Marvin Lerousseau, Eric Deutsh, and Nikos Paragios. Multimodal brain tumor classification, 2020.
  - [25] Pedro Osorio, Guillermo Jimenez-Perez, Javier Montalt-Tordera, Jens Hooge, Guillem Duran-Ballester, Shivam Singh, Moritz Radbruch, Ute Bach, Sabrina Schroeder, Krystyna Siudak, Julia Vienenkoetter, Bettina Lawrenz, and Sadegh Mohammadi. Latent diffusion models with image-derived annotations for enhanced ai-assisted cancer diagnosis in histopathology, 2023.
  - [26] Sierra Bonilla, Shuai Zhang, Dimitrios Psychogios, Danail Stoyanov, Francisco Vasconcelos, and Sophia Bano. Gaussian pancakes: Geometrically-regularized 3d gaussian splatting for realistic endoscopic reconstruction, 2024.
  - [27] Yi Kan Wang, Ludmila Tydlitova, Jeremy D. Kunz, Gerard Oakley, Ran A. Godrich, Matthew C. H. Lee, Chad Vanderbilt, Razik Yousfi, Thomas Fuchs, David S. Klimstra, and Siqi Liu. Screen them all: High-throughput pan-cancer genetic and phenotypic biomarker screening from whole slide images, 2024.
  - [28] Klaudius Scheufele, Shashank Subramanian, and George Biros. Automatic mri-driven model calibration for advanced brain tumor progression analysis, 2020.
  - [29] Shahram Dehdashti, Prayag Tiwari, Kareem H. El Safty, Peter Bruza, and Janis Notzel. Enhancing quantum machine learning: The power of non-linear optical reproducing kernels, 2024.
  - [30] Prakash Adhikari, Aby Panikanthara Binu, Shiva Bhandari, Sheema Khan, Mina Jaggi, Shubhash C. Chauhan, and Prabhakar Pradhan. Optical detection of fractal dimensions of muc13 stained pancreatic tissues for cancer diagnostics, 2018.
  - [31] Bijju Kranthi Veduruparthi, Jayanta Mukherjee, Partha Pratim Das, Moses Arunsingh, Raj Kumar Shrimali, Sriram Prasath, Soumendranath Ray, and Sanjay Chatterjee. Novel radiomic feature for survival prediction of lung cancer patients using low-dose cbct images, 2020.
  - [32] Chul Moon, Qiwei Li, and Guanghua Xiao. Using persistent homology topological features to characterize medical images: Case studies on lung and brain cancers, 2023.
  - [33] Arastu Thakur, Muskan Gupta, Deepak Kumar Sinha, Kritika Kumari Mishra, Vinoth Kumar Venkatesan, and Suresh Guluwadi. Transformative breast cancer diagnosis using cnns with optimized reducelronplateau and early stopping enhancements. *International Journal of Computational Intelligence Systems*, 17(1):14, 2024.
  - [34] Tong Shu, Jun Shi, Dongdong Sun, Zhiguo Jiang, and Yushan Zheng. Slidegcd: Slide-based graph collaborative training with knowledge distillation for whole slide image classification, 2024.

- 
- [35] Yumnah Hasan, Fatemeh Amerehi, Patrick Healy, and Conor Ryan. Stem rebalance: A novel approach for tackling imbalanced datasets using smote, edited nearest neighbour, and mixup, 2023.
  - [36] Ivan Ezhov, Tudor Mot, Suprosanna Shit, Jana Lipkova, Johannes C. Paetzold, Florian Kofler, Fernando Navarro, Chantal Pellegrini, Marcel Kolloviev, Marie Metz, Benedikt Wiestler, and Bjoern Menze. Geometry-aware neural solver for fast bayesian calibration of brain tumor models, 2021.
  - [37] Tonmoy Hossain, Zoraiz Qureshi, Nivetha Jayakumar, Thomas Eluvathingal Muttikkal, Sohil Patel, David Schiff, Miaomiao Zhang, and Bijoy Kundu. Multimodal deep learning to differentiate tumor recurrence from treatment effect in human glioblastoma, 2023.
  - [38] Jiawei Sun, Bin Yang, Nektarios Koukourakis, Jochen Guck, and Juergen W. Czarske. Ai-driven projection tomography with multicore fibre-optic cell rotation, 2023.
  - [39] Yan Xi, Rongbiao Tang, Jingchen Ma, and Jun Zhao. Thickness measurements from single x-ray phase-contrast speckle projection, 2015.
  - [40] Eva Breznik, Elisabeth Wetzer, Joakim Lindblad, and Nataša Sladoje. Cross-modality sub-image retrieval using contrastive multimodal image representations, 2023.
  - [41] Jiayan Li, Lu Bai, Yingna Chen, Junmei Cao, Jingtao Zhu, Wanxiang Zhi, and Qian Cheng. Detecting collagen by machine learning improved photoacoustic spectral analysis for breast cancer diagnostics: feasibility studies with murine models, 2024.
  - [42] Olga Fourkioti, Matt De Vries, Chen Jin, Daniel C. Alexander, and Chris Bakal. Camil: Context-aware multiple instance learning for cancer detection and subtyping in whole slide images, 2024.
  - [43] Kechun Liu, Wenjun Wu, Joann G. Elmore, and Linda G. Shapiro. Semantics-aware attention guidance for diagnosing whole slide images, 2024.
  - [44] Raymond J. Hinton Jr. au2, Jihyun Byun, Dixon Vimalajeewa, and Brani Vidakovic. Ovarian cancer diagnostics using wavelet packet scaling descriptors, 2024.
  - [45] Sarah Schmell, Falk Zakrzewski, Walter de Back, Martin Weigert, Uwe Schmidt, Torsten Wenke, Silke Zeugner, Robert Mantey, Christian Sperling, Ingo Roeder, Pia Hoenscheid, Daniela Aust, and Gustavo Baretton. An interpretable automated detection system for fish-based her2 oncogene amplification testing in histo-pathological routine images of breast and gastric cancer diagnostics, 2020.
  - [46] Luca Beber, Edoardo Lamon, Giacomo Moretti, Daniele Fontanelli, Matteo Saveriano, and Luigi Palopoli. Towards robotised palpation for cancer detection through online tissue vis-coelastic characterisation with a collaborative robotic arm, 2024.
  - [47] Timothy Kwong and Samaneh Mazaheri. A survey on deep learning approaches for breast cancer diagnosis, 2022.
  - [48] Yuan-Peng Zhang, Xin-Yun Zhang, Yu-Ting Cheng, Bing Li, Xin-Zhi Teng, Jiang Zhang, Saikit Lam, Ta Zhou, Zong-Rui Ma, Jia-Bao Sheng, et al. Artificial intelligence-driven radiomics study in cancer: the role of feature engineering and modeling. *Military Medical Research*, 10(1):22, 2023.
  - [49] Marina Zajnulina. Advances of artificial intelligence in classical and novel spectroscopy-based approaches for cancer diagnostics. a review, 2022.
  - [50] Waleed Salah Eldin and Ahmed Kaboudan. Ai-driven medical imaging platform: Advancements in image analysis and healthcare diagnosis. *Journal of the ACS Advances in Computer Science*, 14(1), 2023.
  - [51] Christof A. Bertram, Taryn A. Donovan, Marco Tecilla, Florian Bartenschlager, Marco Fragoso, Frauke Wilm, Christian Marzahl, Katharina Breninger, Andreas Maier, Robert Klopffleisch, and Marc Aubreville. Dataset on bi- and multi-nucleated tumor cells in canine cutaneous mast cell tumors, 2021.

- 
- [52] Ye Zhang, Maoyu Li, Xiaomei Gao, Yongheng Chen, and Ting Liu. Nanotechnology in cancer diagnosis: progress, challenges and opportunities. *Journal of hematology & oncology*, 12:1–13, 2019.
- [53] Review.
- [54] Weihua Li, Chuanyun Li, Tong Zhou, XiuHong Liu, Xiaoni Liu, Xiuhui Li, and Dexi Chen. Role of exosomal proteins in cancer diagnosis. *Molecular cancer*, 16:1–12, 2017.
- [55] Z. V. Jaliashvili, T. D. Medoidze, Z. G. Melikishvili, K. M. Mardaleishvili, and J. J. Ramsden. Real time noninvasive cancer diagnostics, 2005.
- [56] Gabriele De Rubis, Sabna Rajeev Krishnan, and Mary Bebawy. Liquid biopsies in cancer diagnosis, monitoring, and prognosis. *Trends in pharmacological sciences*, 40(3):172–186, 2019.
- [57] Fakrul Islam Tushar. Refining focus in ai for lung cancer: Comparing lesion-centric and chest-region models with performance insights from internal and external validation, 2024.
- [58] Sirvan Khalighi, Kartik Reddy, Abhishek Midya, Krunal Balvantbhai Pandav, Anant Madabhushi, and Malak Abedalthagafi. Artificial intelligence in neuro-oncology: advances and challenges in brain tumor diagnosis, prognosis, and precision treatment. *NPJ precision oncology*, 8(1):80, 2024.
- [59] V. Castillo, J. Tomas Lazaro, and J. Sardanyes. Dynamics and bifurcations in a simple quasispecies model of tumorigenesis, 2014.
- [60] Francesco Strino, Fabio Parisi, Mariann Micsinai, and Yuval Kluger. Trap: a tree approach for fingerprinting subclonal tumor composition, 2013.
- [61] Ievgenia Pastushenko and Cédric Blanpain. Emt transition states during tumor progression and metastasis. *Trends in cell biology*, 29(3):212–226, 2019.
- [62] Yuxiang Wang, Jie Yang, Aaron T Wild, Wei H Wu, Rachna Shah, Carla Danussi, Gregory J Riggins, Kasthuri Kannan, Erik P Sulman, Timothy A Chan, et al. G-quadruplex dna drives genomic instability and represents a targetable molecular abnormality in atrx-deficient malignant glioma. *Nature communications*, 10(1):943, 2019.
- [63] Jie Cheng, Elizaveta Levina, Pei Wang, and Ji Zhu. Sparse ising models with covariates, 2012.
- [64] Craig M Bielski and Barry S Taylor. Homing in on genomic instability as a therapeutic target in cancer. *Nature Communications*, 12(1):3663, 2021.
- [65] Pei Wang, Dennis L. Chao, and Li Hsu. Learning networks from high dimensional binary data: An application to genomic instability data, 2009.
- [66] Yisroel Brumer and Eugene I. Shakhnovich. The importance of dna repair in tumor suppression, 2004.
- [67] Thorsten Mosler, Francesca Conte, Gabriel MC Longo, Ivan Mikicic, Natasja Kreim, Martin M Möckel, Giuseppe Petrosino, Johanna Flach, Joan Barau, Brian Luke, et al. R-loop proximity proteomics identifies a role of ddx41 in transcription-associated genomic instability. *Nature communications*, 12(1):7314, 2021.
- [68] Mara Compagno, Qi Wang, Chiara Pighi, Taek-Chin Cheong, Fei-Long Meng, Teresa Poggio, Leng-Siew Yeap, Elif Karaca, Rafael B Blasco, Fernanda Langellotto, et al. Phosphatidylinositol 3-kinase δ blockade increases genomic instability in b cells. *Nature*, 542(7642):489–493, 2017.
- [69] Jakub Sawicki, Rico Berner, Thomas Löser, and Eckehard Schöll. Modeling tumor disease and sepsis by networks of adaptively coupled phase oscillators, 2021.

- 
- [70] Karen J Mackenzie, Paula Carroll, Carol-Anne Martin, Olga Murina, Adeline Fluteau, Daniel J Simpson, Nelly Olova, Hannah Sutcliffe, Jacqueline K Rainger, Andrea Leitch, et al. cgas surveillance of micronuclei links genome instability to innate immunity. *Nature*, 548(7668):461–465, 2017.
  - [71] V. Salari, Sh. Barzanjeh, M. Cifra, C. Simon, F. Scholkmann, Z. Alirezaei, and J. A. Tuszyński. Towards non-invasive cancer diagnostics and treatment based on electromagnetic fields, optomechanics and microtubules, 2017.
  - [72] Fang li, Zheng an Yao, and Ruijia Yu. Global stability of a pde-ode model for acid-mediated tumor invasion, 2023.
  - [73] John Maciejowski and Titia de Lange. Telomeres in cancer: tumour suppression and genome instability. *Nature reviews Molecular cell biology*, 18(3):175–186, 2017.
  - [74] Ivana Bozic, Tibor Antal, Hisashi Ohtsuki, Hannah Carter, Dewey Kim, Sining Chen, Rachel Karchin, Kenneth W. Kinzler, Bert Vogelstein, and Martin A. Nowak. Accumulation of driver and passenger mutations during tumor progression, 2009.
  - [75] Yingying Xing, Guojing Ruan, Haiwei Ni, Hai Qin, Simiao Chen, Xinyue Gu, Jiamin Shang, Yantong Zhou, Xi Tao, and Lufeng Zheng. Tumor immune microenvironment and its related mirnas in tumor progression. *Frontiers in immunology*, 12:624725, 2021.
  - [76] Spyridon Bakas, Mauricio Reyes, Andras Jakab, Stefan Bauer, Markus Rempfler, Alessandro Crimi, Russell Takeshi Shinohara, Christoph Berger, Sung Min Ha, Martin Rozycski, Marcel Prastawa, Esther Alberts, Jana Lipkova, John Freymann, Justin Kirby, Michel Bilello, Hassan Fathallah-Shaykh, Roland Wiest, Jan Kirschke, Benedikt Wiestler, Rivka Colen, Aikaterini Kotrotsou, Pamela Lamontagne, Daniel Marcus, Mikhail Milchenko, Arash Nazeri, Marc-Andre Weber, Abhishek Mahajan, Ujjwal Baid, Elizabeth Gerstner, Dongjin Kwon, Gagan Acharya, Manu Agarwal, Mahbubul Alam, Alberto Albiol, Antonio Albiol, Francisco J. Albiol, Varghese Alex, Nigel Allinson, Pedro H. A. Amorim, Abhijit Amrutkar, Ganesh Anand, Simon Andermatt, Tal Arbel, Pablo Arbelaez, Aaron Avery, Muneeza Azmat, Pranjal B., W Bai, Subhashis Banerjee, Bill Barth, Thomas Batchelder, Kayhan Batmanghelich, Enzo Battistella, Andrew Beers, Mikhail Belyaev, Martin Bendszus, Eze Benson, Jose Bernal, Halandur Nagaraja Bharath, George Biros, Sotirios Bisdas, James Brown, Mariano Cabezas, Shilei Cao, Jorge M. Cardoso, Eric N Carver, Adrià Casamitjana, Laura Silvana Castillo, Marcel Catà, Philippe Cattin, Albert Cerigues, Vinicius S. Chagas, Siddhartha Chandra, Yi-Ju Chang, Shiyu Chang, Ken Chang, Joseph Chazalon, Shengcong Chen, Wei Chen, Jefferson W Chen, Zhaolin Chen, Kun Cheng, Ahana Roy Choudhury, Roger Chylla, Albert Clérigues, Steven Colleman, Ramiro German Rodriguez Colmeiro, Marc Combalia, Anthony Costa, Xiaomeng Cui, Zhenzhen Dai, Lutao Dai, Laura Alexandra Daza, Eric Deutsch, Changxing Ding, Chao Dong, Shidu Dong, Wojciech Dudzik, Zach Eaton-Rosen, Gary Egan, Guilherme Escudero, Théo Estienne, Richard Everson, Jonathan Fabrizio, Yong Fan, Longwei Fang, Xue Feng, Enzo Ferrante, Lucas Fidon, Martin Fischer, Andrew P. French, Naomi Fridman, Huan Fu, David Fuentes, Yaozong Gao, Evan Gates, David Gering, Amir Gholami, Willi Gierke, Ben Glockner, Mingming Gong, Sandra González-Villá, T. Grosjes, Yuanfang Guan, Sheng Guo, Sudeep Gupta, Woo-Sup Han, Il Song Han, Konstantin Harmuth, Huiguang He, Aura Hernández-Sabaté, Evelyn Herrmann, Naveen Himthani, Winston Hsu, Cheyu Hsu, Xiaojun Hu, Xiaobin Hu, Yan Hu, Yifan Hu, Rui Hua, Teng-Yi Huang, Weilin Huang, Sabine Van Huffel, Quan Huo, Vivek HV, Khan M. Iftekharuddin, Fabian Isensee, Mobarakol Islam, Aaron S. Jackson, Sachin R. Jambawalikar, Andrew Jesson, Weijian Jian, Peter Jin, V Jeya Maria Jose, Alain Jungo, B Kainz, Konstantinos Kamnitsas, Po-Yu Kao, Ayush Karnawat, Thomas Kellermeier, Adel Kermi, Kurt Keutzer, Mohamed Tarek Khadir, Mahendra Khened, Philipp Kickingereder, Geena Kim, Nik King, Haley Knapp, Urspeter Knecht, Lisa Kohli, Deren Kong, Xiangmao Kong, Simon Koppers, Avinash Kori, Ganapathy Krishnamurthi, Egor Krivov, Piyush Kumar, Kaisar Kushibar, Dmitrii Lachinov, Tryphon Lambrou, Joon Lee, Chengan Lee, Yuehchou Lee, M Lee, Szidonia Lefkovits, Laszlo Lefkovits, James Levitt, Tengfei Li, Hongwei Li, Wenqi Li, Hongyang Li, Xiaochuan Li, Yuexiang Li, Heng Li, Zhenye Li, Xiaoyu Li, Zeju Li, XiaoGang Li, Wenqi Li, Zheng-Shen Lin, Fengming Lin, Pietro Lio, Chang Liu, Boqiang Liu, Xiang Liu, Mingyuan Liu, Ju Liu, Luyan Liu, Xavier Llado, Marc Moreno Lopez, Pablo Ribalta Lorenzo, Zhentai Lu, Lin Luo, Zhigang Luo,

---

Jun Ma, Kai Ma, Thomas Mackie, Anant Madabushi, Issam Mahmoudi, Klaus H. Maier-Hein, Pradipta Maji, CP Mammen, Andreas Mang, B. S. Manjunath, Michal Marcinkiewicz, S McDonagh, Stephen McKenna, Richard McKinley, Miriam Mehl, Sachin Mehta, Raghav Mehta, Raphael Meier, Christoph Meinel, Dorit Merhof, Craig Meyer, Robert Miller, Sushmita Mitra, Aliasgar Moiyadi, David Molina-Garcia, Miguel A. B. Monteiro, Grzegorz Mrukwa, Andriy Myronenko, Jakub Nalepa, Thuyen Ngo, Dong Nie, Holly Ning, Chen Niu, Nicholas K Nuechterlein, Eric Oermann, Arlindo Oliveira, Diego D. C. Oliveira, Arnau Oliver, Alexander F. I. Osman, Yu-Nian Ou, Sebastien Ourselin, Nikos Paragios, Moo Sung Park, Brad Paschke, J. Gregory Pauloski, Kamlesh Pawar, Nick Pawlowski, Linmin Pei, Suting Peng, Silvio M. Pereira, Julian Perez-Beteta, Victor M. Perez-Garcia, Simon Pezold, Bao Pham, Ashish Phophalia, Gemma Piella, G. N. Pillai, Marie Piraud, Maxim Pisov, Anmol Popli, Michael P. Pound, Reza Pourreza, Prateek Prasanna, Vesna Prkovska, Tony P. Pridmore, Santi Puch, Élodie Puybareau, Buyue Qian, Xu Qiao, Martin Rajchl, Swapnil Rane, Michael Rebsamen, Hongliang Ren, Xuhua Ren, Karthik Revanuru, Mina Rezaei, Oliver Rippel, Luis Carlos Rivera, Charlotte Robert, Bruce Rosen, Daniel Rueckert, Mohammed Safwan, Mostafa Salem, Joaquim Salvi, Irina Sanchez, Irina Sánchez, Heitor M. Santos, Emmett Sartor, Dawid Schellingherhout, Klaudius Scheufele, Matthew R. Scott, Artur A. Scussel, Sara Sedlar, Juan Pablo Serrano-Rubio, N. Jon Shah, Nameetha Shah, Mazhar Shaikh, B. Uma Shankar, Zeina Shboul, Haipeng Shen, Dinggang Shen, Linlin Shen, Haocheng Shen, Varun Shenoy, Feng Shi, Hyung Eun Shin, Hai Shu, Diana Sima, M Sinclair, Orjan Smedby, James M. Snyder, Mohammadreza Soltaninejad, Guidong Song, Mehul Soni, Jean Stawiaski, Shashank Subramanian, Li Sun, Roger Sun, Jiawei Sun, Kay Sun, Yu Sun, Guoxia Sun, Shuang Sun, Yannick R Suter, Laszlo Szilagyi, Sanjay Talbar, Dacheng Tao, Dacheng Tao, Zhongzhao Teng, Siddhesh Thakur, Meenakshi H Thakur, Sameer Tharakan, Pallavi Tiwari, Guillaume Tochon, Tuan Tran, Yuhsiang M. Tsai, Kuan-Lun Tseng, Tran Anh Tuan, Vadim Turlapov, Nicholas Tustison, Maria Vakalopoulou, Sergi Valverde, Rami Vanguri, Evgeny Vasiliev, Jonathan Ventura, Luis Vera, Tom Vercauteren, C. A. Verrastro, Lasitha Vidyardatne, Veronica Vilaplana, Ajeet Vivekanandan, Guotai Wang, Qian Wang, Chiatse J. Wang, Weichung Wang, Duo Wang, Ruixuan Wang, Yuanyuan Wang, Chunliang Wang, Guotai Wang, Ning Wen, Xin Wen, Leon Weninger, Wolfgang Wick, Shaocheng Wu, Qiang Wu, Yihong Wu, Yong Xia, Yanwu Xu, Xiaowen Xu, Peiyuan Xu, Tsai-Ling Yang, Xiaoping Yang, Hao-Yu Yang, Junlin Yang, Haojin Yang, Guang Yang, Hongdou Yao, Xujiong Ye, Changchang Yin, Brett Young-Moxon, Jinhua Yu, Xiangyu Yue, Songtao Zhang, Angela Zhang, Kun Zhang, Xuejie Zhang, Lichi Zhang, Xiaoyue Zhang, Yazhuo Zhang, Lei Zhang, Jianguo Zhang, Xiang Zhang, Tianhao Zhang, Sicheng Zhao, Yu Zhao, Xiaomei Zhao, Liang Zhao, Yefeng Zheng, Liming Zhong, Chenhong Zhou, Xiaobing Zhou, Fan Zhou, Hongtu Zhu, Jin Zhu, Ying Zhuge, Weiwei Zong, Jayashree Kalpathy-Cramer, Keyvan Farahani, Christos Davatzikos, Koen van Leemput, and Bjoern Menze. Identifying the best machine learning algorithms for brain tumor segmentation, progression assessment, and overall survival prediction in the brats challenge, 2019.

- [77] Lidia Garrucho, Kaisar Kushibar, Claire-Anne Reidel, Smriti Joshi, Richard Osuala, Apostolia Tsirikoglou, Maciej Bobowicz, Javier del Riego, Alessandro Catanese, Katarzyna Gwoździewicz, Maria-Laura Cosaka, Pasant M. Abo-Elhoda, Sara W. Tantawy, Shorouq S. Sakrana, Norhan O. Shawky-Abdelfatah, Amr Muhammad Abdo-Salem, Androniki Kozana, Eugen Divjak, Gordana Ivanac, Katerina Nikiforaki, Michail E. Klontzas, Rosa García-Dosdá, Meltem Gulsun-Akpınar, Oğuz Lafçı, Ritse Mann, Carlos Martín-Isla, Fred Prior, Kostas Marias, Martijn P. A. Starmans, Fredrik Strand, Oliver Díaz, Laura Igual, and Karim Lekadir. A large-scale multicenter breast cancer dce-mri benchmark dataset with expert segmentations, 2025.
- [78] Zura Kakushadze and Willie Yu. Mutation clusters from cancer exome, 2017.
- [79] Jiong Yan, Peixing Wan, Swati Choksi, and Zheng-Gang Liu. Necroptosis and tumor progression. *Trends in cancer*, 8(1):21–27, 2022.
- [80] Qinsi Wang, Natasa Miskov-Zivanov, Bing Liu, James R. Faeder, Michael Lotze, and Edmund M. Clarke. Formal modeling and analysis of pancreatic cancer microenvironment, 2016.

- 
- [81] Christian Strack, Kelsey L. Pomykala, Heinz-Peter Schlemmer, Jan Egger, and Jens Kleesiek. 'a net for everyone': fully personalized and unsupervised neural networks trained with longitudinal data from a single patient, 2022.
- [82] Hai Qin, Haiwei Ni, Yichen Liu, Yaqin Yuan, Tao Xi, Xiaoman Li, and Lufeng Zheng. Rna-binding proteins in tumor progression. *Journal of hematology & oncology*, 13:1–23, 2020.
- [83] Ivan Ezhov, Jana Lipkova, Suprosanna Shit, Florian Kofler, Nore Collomb, Benjamin Lemasson, Emmanuel Barbier, and Bjoern Menze. Neural parameters estimation for brain tumor growth modeling, 2020.
- [84] K. Bartha and H. Rieger. Vascular network remodeling via vessel cooption, regression and growth in tumors, 2005.
- [85] Yang Yang, Hongmei Zheng, Yuting Zhan, and Songqing Fan. An emerging tumor invasion mechanism about the collective cell migration. *American journal of translational research*, 11(9):5301, 2019.
- [86] Federico Bocci, Herbert Levine, José Nelson Onuchic, and Mohit Kumar Jolly. Deciphering the dynamics of epithelial-mesenchymal transition and cancer stem cells in tumor progression, 2018.
- [87] Caterina Guiot, Nicola Pugno, Pier Paolo Delsanto, and Thomas S. Deisboeck. Physical aspects of cancer invasion, 2007.
- [88] Ushasi Roy, Tyler Collins, Mohit K. Jolly, and Parag Katira. Biophysical and biochemical mechanisms underlying collective cell migration in cancer metastasis, 2022.
- [89] Johannes G. Reiter, Ivana Bozic, Krishnendu Chatterjee, and Martin A. Nowak. Ttp: Tool for tumor progression, 2013.
- [90] Sylvie Brassart-Pasco, Stéphane Brézillon, Bertrand Brassart, Laurent Ramont, Jean-Baptiste Oudart, and Jean Claude Monboisse. Tumor microenvironment: extracellular matrix alterations influence tumor progression. *Frontiers in oncology*, 10:397, 2020.
- [91] Theresa L Whiteside. Tumor-infiltrating lymphocytes and their role in solid tumor progression. In *Interaction of immune and cancer cells*, pages 89–106. Springer, 2022.
- [92] Alex M. Hruska, Haiqian Yang, Susan E. Leggett, Ming Guo, and Ian Y. Wong. Mechanobiology of collective cell migration in 3d microenvironments, 2022.
- [93] Olga Ilina, Pavlo G Gritsenko, Simon Syga, Jürgen Lippoldt, Caterina AM La Porta, Oleksandr Chepizhko, Steffen Grosser, Manon Vullings, Gert-Jan Bakker, Jörn Starruß, et al. Cell-cell adhesion and 3d matrix confinement determine jamming transitions in breast cancer invasion. *Nature cell biology*, 22(9):1103–1115, 2020.
- [94] Subhaya Bose, Haiqin Wang, Xinpeng Xu, Arvind Gopinath, and Kinjal Dasbiswas. Elastic interactions compete with persistent cell motility to drive durotaxis, 2024.
- [95] Giulia Chiari, Martina Conte, and Marcello Delitala. Multi-scale modeling of snail-mediated response to hypoxia in tumor progression, 2024.
- [96] Rachel A Battaglia, Samed Delic, Harald Herrmann, and Natasha T Snider. Vimentin on the move: new developments in cell migration. *F1000Research*, 7:F1000–Faculty, 2018.
- [97] Xinxun Bao, Yanan Zhang, Hairong Zhang, and Lei Xia. Molecular mechanism of  $\beta$ -sitosterol and its derivatives in tumor progression. *Frontiers in oncology*, 12:926975, 2022.
- [98] Temitope O Benson, Mohammad Aminul Islam, Kailei Liu, and Ashlee N Ford Versypt. Agent-based modeling reveals impacts of cell adhesion and matrix remodeling on cancer collective cell migration phenotypes. *bioRxiv*, pages 2024–12, 2024.
- [99] Torben Sunkel, Lukas Hupe, and Philip Bittihn. Motility-induced mixing transition in exponentially growing multicellular spheroids, 2025.

- 
- [100] Tibor Antal and P. L. Krapivsky. Exact solution of a two-type branching process: Models of tumor progression, 2011.
  - [101] Rick Durrett, Jasmine Foo, Kevin Leder, John Mayberry, and Franziska Michor. Evolutionary dynamics of tumor progression with random fitness values, 2010.
  - [102] Le Zhang, Costas G. Strouthos, Zhihui Wang, and Thomas S. Deisboeck. Simulating brain tumor heterogeneity with a multiscale agent-based model: Linking molecular signatures, phenotypes and expansion rate, 2007.
  - [103] Charalampos E. Tsourakakis. Modeling intratumor gene copy number heterogeneity using fluorescence in situ hybridization data, 2013.
  - [104] Monica Fedele, Riccardo Sgarra, Sabrina Battista, Laura Cerchia, and Guidalberto Manfioletti. The epithelial–mesenchymal transition at the crossroads between metabolism and tumor progression. *International journal of molecular sciences*, 23(2):800, 2022.
  - [105] Youness Azimzade, Abbas Ali Saberi, and Robert A. Gatenby. Super-linear growth reveals the allee effect in tumors, 2021.
  - [106] Kairui Guo, Mengjia Wu, Zelia Soo, Yue Yang, Yi Zhang, Qian Zhang, Hua Lin, Mark Grosser, Deon Venter, Guangquan Zhang, et al. Artificial intelligence-driven biomedical genomics. *Knowledge-Based Systems*, page 110937, 2023.
  - [107] Weina Jin, Mostafa Fatehi, Kumar Abhishek, Mayur Mallya, Brian Toyota, and Ghassan Hamarneh. Artificial intelligence in glioma imaging: Challenges and advances, 2020.
  - [108] Daniel Mas Montserrat, Arvind Kumar, Carlos Bustamante, and Alexander Ioannidis. Addressing ancestry disparities in genomic medicine: A geographic-aware algorithm, 2020.

---

**Disclaimer:**

SurveyX is an AI-powered system designed to automate the generation of surveys. While it aims to produce high-quality, coherent, and comprehensive surveys with accurate citations, the final output is derived from the AI's synthesis of pre-processed materials, which may contain limitations or inaccuracies. As such, the generated content should not be used for academic publication or formal submissions and must be independently reviewed and verified. The developers of SurveyX do not assume responsibility for any errors or consequences arising from the use of the generated surveys.

www.SurveyX.Cn